LEADER 04450nam 22006975 450 001 9910300333103321 005 20200707022356.0 010 $a3-642-45195-0 024 7 $a10.1007/978-3-642-45195-9 035 $a(CKB)3710000000089195 035 $a(EBL)1698373 035 $a(OCoLC)881161842 035 $a(SSID)ssj0001166514 035 $a(PQKBManifestationID)11657049 035 $a(PQKBTitleCode)TC0001166514 035 $a(PQKBWorkID)11121117 035 $a(PQKB)10365258 035 $a(MiAaPQ)EBC1698373 035 $a(DE-He213)978-3-642-45195-9 035 $a(PPN)176750177 035 $a(EXLCZ)993710000000089195 100 $a20140215d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aProstate Cancer Prevention /$fedited by Jack Cuzick, Mangesh A. Thorat 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (167 p.) 225 1 $aRecent Results in Cancer Research,$x0080-0015 ;$v202 300 $aDescription based upon print version of record. 311 $a3-642-45194-2 320 $aIncludes bibliographical references. 327 $aBiology and natural history of prostate cancer -- Nutrition and prostate cancer -- Prostate cancer chemoprevention -- Lifestyle and dietary factors -- GWAS in prostate cancer predisposition and application to screening and prevention -- Risk prediction biomarkers ? CCP -- Risk prediction biomarkers - TMPRSS2-ERG -- Risk prediction biomarkers ? PCA3 -- Risk adapted chemoprevention for PCa -- Outlook for 5? reductase inhibitors in prostate cancer prevention -- Prostate cancer chemoprevention: Aspirin -- Prostate cancer chemoprevention: DFMO -- Prostate cancer chemoprevention: Lycopene -- Distinguishing aggressive from indolent prostate cancer -- Prognosis and Management of low grade disease - Management of Gleason 6 -- Prostate cancer prevention: Policy & Research implications. 330 $aProstate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely.   A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5?-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers. 410 0$aRecent Results in Cancer Research,$x0080-0015 ;$v202 606 $aOncology   606 $aUrology 606 $aCancer research 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aUrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H62002 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 615 0$aOncology  . 615 0$aUrology. 615 0$aCancer research. 615 14$aOncology. 615 24$aUrology. 615 24$aCancer Research. 676 $a616.99463 686 $aXH 2200$2rvk 702 $aCuzick$b Jack$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aThorat$b Mangesh A$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300333103321 996 $aProstate Cancer Prevention$91522993 997 $aUNINA